p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung by Huang, C-I et al.
It is widely accepted that malignant tumours are caused by the
accumulation of genetic alterations (Vogelstein et al, 1988; Chung
et al, 1995). These genetic alterations regulate the malignant
behaviour of solid tumours, such as tumour rapid growth (Cordon-
Cardo, 1995) and metastatic potential (Miyake et al, 1991; Dong
et al, 1995). Non-small-cell lung cancers (NSCLC) are also
variably affected by the activation of oncogenes such as K-ras
(Rodenhuis and Slebos, 1992), or the inactivation of tumour
suppressor genes such as p53 (Takahashi et al, 1989), p16INK4 (Vos
et al, 1995), and retinoblastoma (RB) (Reissmann et al, 1993),
which principally control the cell cycle and tumour growth. Such
heterogeneity in the aetiologic genetic alterations might be one of
the reasons for the variety of clinical behaviours of NSCLCs.
Therefore, it is important to classify NSCLCs according to their
gene status, which might reflect biological behaviour. Reliable and
sensitive prognostic parameters would help us to identify those
patients for whom intensive adjuvant therapy is necessary.
Especially, it seems justified to evaluate the effects of surgery with
adjuvant chemotherapy or radiotherapy.
However, our previous study on mutations of the p53 and K-ras
genes in Japanese patients with NSCLC showed that only 41.7%
of these patients had mutations in either of the two genes (Huang
et al, 1998), and that a genetic classification accounting for only
these two genes was insufficient to predict the biological behav-
iour of NSCLCs. The p16INK4A gene belongs to the G1 control
gene, which includes RB (Betticher et al, 1997). This gene is also
believed to be a tumour suppressor gene, and inactivation of
p16INK4 has been detected in various human malignant tumours
(Nobori et al, 1994; Reed et al, 1996). Several studies have
reported that p16INK4 alterations occurred in about 27.0–54.0% of
NSCLCs (Kratzke et al, 1996; Betticher et al, 1997; Taga et al,
1997; Kashiwabara et al, 1998; Tanaka et al, 1998), but their prog-
nostic significance in NSCLC patients remain unclear (Kratzke et
al, 1996; Marchetti et al, 1997; Taga et al, 1997; Volm et al, 1998;
Geradts et al, 1999). Therefore, in order to make a more accurate
and useful genetic classification of NSCLC, we performed a
further study focusing on the p16INK4A status.
MATERIALS AND METHODS
Clinical characteristics of patients
From January 1991 to December 1994, patients who underwent
surgery at the Department of Surgery of the Osaka Medical Center
for Cancer and Cardiovascular Diseases and at the Department of
Thoracic Surgery of the Kitano Hospital, Medical Research
Institute of Osaka in Japan, were studied. Tumour-node-metastasis
(TNM) staging designations were made according to the post-
surgical pathological international staging system (Mountain,
1997). Because advanced stage lung cancer (stage IV) involved
several ill-defined factors and had distant metastases, these
patients were excluded from this study. Patients with two or more
forms of cancers and those who died of causes other than lung
cancer were also excluded from this study. In total, 171 patients
with lung cancer up to stage IIIB, which included 106 patients
with adenocarcinomas, 55 patients with SCCs and ten patients
with large cell carcinomas, were investigated. The patients’
clinical records and histopathological diagnoses were fully
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documented. This report includes follow-up data as of 1 March
1998. The median follow-up period for all patients was 58.5 ± 14.3
months.
All patients with N2 or N3 status underwent mediastinal radio-
therapy (50 Gy in 25 fractions for a period of 5 weeks) after the
surgical resection, and were then treated by two cycles of adjuvant
chemotherapy including cisplatin (80 mg per square metre of
body-surface area given intravenously (i.v.) on day 1) and vinde-
sine (4 mg per square metre of body-surface area given i.v. on day
1, 8 and 15). Ten patients with T3 or T4 status, who were found to
have undergone an incomplete resection, also received radio-
therapy (50 Gy in 25 fractions for a period of 5 weeks) for micro-
scopic-positive margins. The other patients had no radiotherapy
before recurrence. Post-operative adjuvant systemic chemotherapy
was given according to the nodal status. Of the 69 node-positive
patients, 63 patients underwent adjuvant chemotherapy with two
cycles of cisplatin and vindesine. Of the 102 node-negative
patients, 97 patients did not have any further adjuvant treatments.
We detected distant metastases in 75 patients during the observa-
tion period, and among these 75 patients, 11 patients also had
local recurrences. Six patients had only locoregional recurrences.
After the recurrence, the locoregional tumours or lymph nodes
were principally treated with radiotherapy. Patients with distant
metastases were treated with a different chemotherapy regime
including cisplatin and etoposide.
Immunohistochemistry for p16 protein expression
We studied the immunohistochemical study for p16 protein
expression using a mouse monoclonal antibody detecting the full-
length human p16 protein (PharMingen, Inc., San Diego, CA,
USA, clone G175–405) as described previously (Betticher et al,
1997; Vonlanthen et al, 1998). In a pilot study, initially we
performed the immunohistochemistry with microwave pretreat-
ment and that without microwave pretreatment. Thus, microwave
pretreatment was preferable because of good contrast using this
antibody. Formalin-fixed paraffin-embedded tissues were cut in
4-mm sections and mounted on poly-L-lysine-coated slides. The
sections were deparaffinized and rehydrated. The slides were
heated in a microwave for 10 min in a 10-mmol l–1 citrate buffer
solution at pH 6.0, and cooled down to room temperature for at
least 20 min. After quenching the endogenous peroxidase activity
with 0.3% hydrogen peroxide (in absolute methanol) for 30 min,
the sections were treated for 2 h at room temperature with 5%
bovine serum albumin to block non-specific staining.
Subsequently, the slides were incubated at 4°C overnight with the
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Figure 1 Immunohistochemical staining of human non-small-cell lung cancer tissues using the avidin–biotin–peroxidase complex procedure (Bars = 50 mm).
(A) Adenocarcinoma with positive p16 expression. (B) Adenocarcinoma with negative p16 expression. (C) Squamous cell carcinoma with positive p16
expression. (D) Squamous cell carcinoma with negative p16 expression376 C-I Huang et al
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anti-p16 antibody at a 1:100 dilution. Then, the slides were washed
three times in phosphate-buffered saline (PBS), and then incubated
for 1 h with biotinylated horse anti-mouse IgG. After being
washed three times in PBS, the sections were incubated with the
avidin–biotin–peroxidase complex (Vector) for 1 h and then
washed in PBS for 10 min. Antibody binding was visualized with
3,3¢-diaminobenzidine tetrahydrochloride, and the sections coun-
terstained lightly with Mayer’s haematoxylin. There was no differ-
ence in staining intensity between peripheral and central portions
of the tissues, except for the edge effect, common to immunohisto-
chemical assays. All immunostained sections were reviewed by
two pathologists who had no knowledge of the patients’ clinical
status.
p16 immunostaining was assessed by comparison of type II
pneumocytes, normal bronchial cells and some endothelial cells as
the positive internal control. And, small lymphocytes without
nuclear staining of p16 were used as a negative internal control.
For scoring the p16 staining patterns, only nuclear staining above
any cytoplasmic background was considered to be positive for p16
protein expression. Tumours were classified as p16-positive
(p16+) when the proportion of stained nuclei was ³ 10% of all
nuclei in the tumour. Thus, tumours were evaluated as p16-nega-
tive (p16–) when the proportion of stained nuclei was < 10% of all
nuclei in the tumour. Cytoplasmic staining alone was considered
as p16-negative (Taga et al, 1997; Gazzeri et al, 1998).
Statistical analysis
Clinical data including smoking habits were extracted from the
clinical records. The overall cancer-specific survival was defined
from the data of the operation to the data of cancer death. The
statistical significance of differences in p16 status in relation to
several clinical and pathological parameters was assessed by the c2
test. The Kaplan–Meier method was used to estimate the proba-
bility of overall survival as function of time, and the survival
periods were compared using the log-rank test (Kaplan and Meier,
1958; Mantel, 1966). Multivariate analyses were performed using
the Cox regression model with the SAS statistical package (SAS
Institute, Cary, NC, USA) (Cox, 1972). Scores were assigned to
each variable for the regression analysis. All P-values were based
on two-tailed statistical analysis, and a P-value of less than 0.05
was considered to indicate statistical significance.
RESULTS
Distribution of p16 protein expression in resected
NSCLC tumours
Of the 171 NSCLCs we studied, 23 carcinomas (13.5%) had
nuclear staining in ³ 70% of tumour cells, 45 carcinomas (26.3%)
had nuclear staining in 30–70% of tumour cells, 41 carcinomas
Table 1 Distribution of 171 non-small-cell lung cancer patients according to p16 status
Histology Non-small-cell lung cancer Adenocarcinoma Squamous cell carcinoma
variables n p16+ p16– P-value n p16+ p16– P-value n p16+ p16– P-value
Smoking
Non-smoker 49 34 15 0.331 44 31 13 0.638 4 2 2 0.910
Smoker 122 75 47 62 41 21 51 27 24
Age at surgery
≤60 60 41 19 0.359 44 33 11 0.189 12 5 7 0.385
>60 111 68 43 62 39 23 43 24 19
Sex
Male 127 80 47 0.729 68 46 22 0.935 50 27 23 0.659
Female 44 29 15 38 26 12 5 2 3
Tumour status
T1 46 33 13 0.453 30 23 7 0.527 14 8 6 0.464
T2 77 45 32 45 30 15 26 11 15
T3 34 21 13 21 12 9 11 7 4
T4 14 10 4 10 7 3 4 3 1
Nodal status
N0 102 66 36 0.363 61 40 21 0.168 35 22 13 0.207
N1 24 13 11 12 7 5 10 4 6
N2 38 27 11 28 23 5 9 3 6
N 3 734 52 3 1 01
Pathological stage
Stage I 80 51 29 0.981 47 33 14 0.270 29 16 13 0.428
Stage II 36 22 14 21 11 10 11 7 4
Stage IIIA 35 23 12 24 19 5 10 3 7
Stage IIIB 20 13 7 14 9 5 5 3 2
Differentiation
Well 33 22 11 0.319 26 20 6 0.444 7 2 5 0.243
Moderately 81 47 34 48 30 18 33 17 16
Poorly 57 40 17 32 22 10 15 10 5
Histology
Adeonocarcinoma 106 72 34 0.039
Squamous cell carcinoma 55 29 26
Large cell carcinoma 10 8 2
Total number of patients 171 109 62 106 72 34 55 29 26p16 in non-small cell lung cancer 377
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(24.0%) had nuclear staining in 10–30% of tumour cells, and 62
carcinomas (36.3%) had nuclear staining in <10% of tumour cells.
Thus, 109 carcinomas (63.7%) were classified as p16-positive,
and 62 carcinomas (36.3%) were p16-negative (Figure 1 and
Table 1). Of the 106 adenocarcinomas of the lung, 34 tumours
(32.1%) were p16-negative. Of the 55 SCCs, 26 tumours (47.3%)
were p16-negative. p16-negative tumours in SCCs were signifi-
cantly more than those in adenocarcinomas (P = 0.039). However,
there were no statistically significant relationships between p16
expression and smoking habits, the patient’s age at surgery,
gender, tumour status, nodal status, pathological stage and tumour
differentiation (Table 1).
Overall survival of patients with NSCLCs in relation to
p16 status
The 5-year survival rate of all 171 patients stratified according to
their p16 status was shown in Table 2. No significant difference
was found in the 5-year survival of NSCLC patients with p16-
negative tumours versus those with p16-positive tumours (51.0%
vs 62.2%, Figure 2A and Table 2). However, the survival of
patients with p16-negative tumours was significantly worse than
that of patients with p16-positive tumours in the early stage of
NSCLC, such as stage I, T1 status and N0 status (P < 0.001,
P = 0.008 and P = 0.003 respectively; Figure 2B and Table 2).
A Cox regression analysis was performed to evaluate prognostic
factors for NSCLC, as shown in Table 3. Among the 171 NSCLC
patients, only the nodal status was found to be a significant factor
for the prognosis (hazard ratio = 1.956, P < 0.001).
Overall survival of patients with adenocarcinomas of
the lung in relation to p16 status
The 5-year survival rate of the 106 patients with adenocarcinomas
stratified according to their p16 status is shown in Table 2. There
was no significant difference in the 5-year survival between
patients with p16-negative adenocarcinomas and those with p16-
positive adenocarcinomas (51.8% vs 54.3%, Figure 2C), even in
the early stage of adenocarcinoma.
A Cox regression analysis to evaluate prognostic factors for
adenocarcinoma showed that two variables, the tumour status
(hazard ratio = 1.488, P = 0.024) and the nodal status (hazard ratio
= 1.756, P < 0.001) were found to be significant factors for the
prognosis (Table 3).
Overall survival of patients with SCCs of the lung in
relation to p16 status
Of the 55 patients with squamous cell carcinomas, the 5-year
survival rate of patients with p16-negative tumours was signifi-
cantly lower than those with p16-positive tumours (45.5% vs
86.2%,  P = 0.001, Figure 2D and Table 2). Especially, the survival
of patients with p16-negative tumours was significantly worse
than those with p16-positive tumours in the early stage of SCC,
such as stage I, T1 status and N0 status (P = 0.005, P = 0.046 and
P < 0.001 respectively; Figure 2E and Table 2). In addition, the
survival of patients with p16-negative tumours was significantly
worse than those with p16-positive tumours in moderately
and poorly differentiated tumours (P = 0.031 and P = 0.025
respectively).
Table 2 Five-year survival rate of 171 non-small-cell lung cancer patients according to p16 status
Histology Non-small-cell lung cancer Adenocarcinoma Squamous cell carcinoma
variables p16+ p16– P-value p16+ p16– P-value p16+ p16– P-value
Smoking
Non-smoker 71.9 65.2 0.353 72.5 75.2 0.769 100.0 0.0 0.333
Smoker 58.5 46.4 0.179 41.5 34.9 0.985 85.2 49.2 0.006
Age at surgery
≤60 50.9 44.4 0.807 48.6 29.1 0.866 80.0 38.1 0.299
>60 69.1 52.7 0.028 59.0 54.8 0.721 87.5 47.4 0.003
Sex
Male 60.9 46.9 0.119 47.5 39.0 0.766 85.2 47.4 0.004
Female 67.2 64.2 0.441 67.5 72.9 0.860 100.0 33.3 0.400
Tumour status
T1 87.9 52.7 0.008 87.0 57.1 0.065 100.0 44.4 0.046
T2 59.2 53.2 0.298 49.8 52.4 0.783 90.9 46.7 0.019
T3 42.9 46.2 0.645 25.0 55.6 0.192 71.4 25.0 0.293
T4 30.0 0.0 0.351 14.3 0.0 0.225 66.7 0.0 >0.999
Nodal status
N0 83.2 60.7 0.003 77.5 62.3 0.193 95.5 51.3 <0.001
N1 44.9 63.6 0.665 28.6 80.0 0.179 75.0 50.0 0.435
N2 22.2 27.3 0.783 17.4 20.0 0.217 33.3 33.3 0.749
N3 0.0 0.0 0.153 0.0 0.0 0.207 (–) 0.0 ND
Pathological stage
Stage I 90.0 58.6 <0.001 84.8 58.9 0.104 100.0 51.3 0.005
Stage II 54.2 71.4 0.502 36.4 80.0 0.098 85.7 50.0 0.155
Stage IIIA 26.1 25.0 0.520 42.1 20.0 0.105 33.3 28.6 0.772
Stage IIIB 23.1 0.0 0.578 0.0 0.0 0.281 66.7 0.0 0.592
Differentiation
Well 81.8 63.6 0.227 80.0 66.7 0.403 100.0 60.0 >0.999
Moderately 63.0 52.5 0.361 51.9 60.5 0.508 82.4 41.7 0.031
Poorly 50.8 40.3 0.292 34.1 30.0 0.803 90.0 0.0 0.025
Total number of patients 62.2 51.0 0.071 54.3 51.8 0.768 86.2 45.5 0.001
ND, not done.378 C-I Huang et al
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A Cox regression analysis to evaluate the prognostic factors
for SCC showed that two variables, the p16 status (hazard
ratio = 3.939, P = 0.024) and the nodal status (hazard ratio = 2.310,
P = 0.008) were significant factors for the prognosis
(Table 3).
DISCUSSION
p16INK4A is located at 9p21 on chromosome and encodes a cyclin-
dependent kinase (cdk) inhibitor which is an important cell cycle
regulatory element (Serrano et al, 1993). The p16 protein binds
both cdk4 and cdk6, and negatively regulates the cyclin D-depen-
dent phosphorylation of the RB protein, thereby inhibiting the cell
cycle transition from G1 to S phase by sequestering of a transacti-
vation factor of E2F (Serrano et al, 1993; Lukas et al, 1995).
Therefore, a loss of p16 function could disrupt the RB-mediated
tumour suppressor pathway. The mechanisms of inactivation of
p16INK4A in patients with NSCLCs are believed to be a homozygous
deletion (Shimizu and Sekiya, 1995; Vos et al, 1995) and hyper-
methylation of the CpG island in the promoter region of the
p16INK4A gene (Herman et al, 1995; Merlo et al, 1995). In addition,
mutations of the p16INK4A gene were not detected frequently in
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C Figure 2 (A) Overall survival of 171 patients with non-small-cell lung
cancers according to their tumour p16 status. (B) Overall survival of
80 patients with stage I NSCLCs according to their tumour p16 status.
(C) Overall survival of 106 patients with adenocarcinomas of the lung
according to their tumour p16 status. (D) Overall survival of 55 patients with
squamous cell carcinomas of the lung according to their tumour p16 status.
(E) Overall survival of 29 patients with stage I squamous cell carcinomas of
the lung according to their tumour p16 statusp16 in non-small cell lung cancer 379
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patients with NSCLCs (Nakagawa et al, 1995; Gazzeri et al,
1998). The clinical significance of the p16 status in NSCLCs is
still controversial, partly because various methods have been used
in a relatively small population of patients. Recently, the immuno-
histochemical detection of p16 is considered to be a sensitive and
suitable method to screen for p16 alterations and appears to be
superior to any other method for detecting genetic alterations
(Gazzeri et al, 1998). Therefore, we evaluated the expression of
the p16 protein by immunohistochemistry in this study.
Of the 171 NSCLCs we studied, 23 carcinomas (13.5%) showed
strong p16 protein expression with nuclear staining in > 70% of
tumour cells. Such tumours might be associated with an inactive
RB protein. The p16INK4 and RB genes constitute a single pathway
and regulate each other by a feedback mechanism. Several
previous studies have reported the inverse relationship between
p16INK4 expression and RB expression (Otterson et al, 1994;
Shapiro et al, 1995; Sakaguchi et al, 1996).
As previously reported, there was no relationship between the
p16 status and the pathological stage in adenocarcinomas as well
as in SCCs. Twenty-nine (36.3%) of 80 patients with stage I
NSCLCs had alterations of p16. Therefore, loss of p16 occurs at a
relatively early stage, and may play an important role in the
progression of some NSCLCs (Kinoshita et al, 1996; Taga et al,
1997). Previous clinical studies have reported that genetic alter-
ations of p16INK4 occurred in about 27.0–54.0% of resected
NSCLCs (Kratzke et al, 1996; Betticher et al, 1997; Taga et al,
1997; Kashiwabara et al, 1998; Tanaka et al, 1998), which is in
agreement with our results. Furthermore, with respect to the
histology of NSCLC, p16 alterations have been reported to occur
in 21.2–75.0% of SCCs, and in 20.3–41.5% of adenocarcinomas.
Most studies have shown a high prevalence of p16 alterations in
SCCs, as our results confirmed.
With respect to the survival of NSCLC patients, our study
demonstrated that the alteration of p16 was one of the significant
factors for a poor prognosis in SCCs of the lung, especially in the
early stage such as stage I and N0 status. Several studies also
reported that the loss of p16 was one of the significant factors for
the poor survival in NSCLCs, especially in early stage of SCC
(Kratzke et al, 1996; Taga et al, 1997). On the Cox multivariate
analysis of SCCs, the p16 status had a hazard ratio of 3.939 for
survival. The 5-year survival of patients with p16-negative SCC
was only 51.3% even in stage I. On the other hand, no patient with
stage I SCC had a recurrence after the surgery in our series.
Therefore, in patients with p16-negative SCCs of the lung, adju-
vant chemoradiotherapy after surgery might be useful even if they
are in the early stage, whereas no adjuvant therapy might be
recommended for surgically-treated patients with p16-positive
SCC in the early stage.
However, the loss of p16 expression had no prognostic impact
in adenocarcinomas of the lung, which coincided with the previous
report (Volm et al, 1998). From previous clinical studies including
ours, mutations of p53 and mutations of K-ras have been reported
to be useful factors indicative of a poor prognosis in adenocarci-
nomas of the lung (Fukuyama et al, 1997; Huang et al, 1998). The
different biological mechanisms among p16INK4, p53 and K-ras
might have a strong effect on the survival between patients with
SCCs and those with adenocarcinomas. For example, with respect
to the clinical behaviour of the tumour, SCCs are likely to relapse
in locoregional region, whereas adenocarcinomas are likely to
have distant metastasis even when the primary tumours are still
small (Minna, 1991). The alterations of p16INK4 gene have been
reported to be associated with tumour proliferative activity and
tumour growth. On the other hand, mutations of the K-ras gene,
which was believed to be specific for adenocarcinomas of the
Table 3 Multivariate regression analysis in predicting survival of 171 patients with non-small-cell lung cancer
Histology Non-small-cell lung cancer Adenocarcinoma Squamous cell carcinoma
variables Assigned Hazard (95% CI) P-value Hazard (95% CI) P-value Hazard (95% CI) P-value
score ratio ratio ratio
p16 status
Positive 0 1.225 (0.749–2.003) 0.419 0.764 (0.401–1.455) 0.413 3.939 (1.196–12.972) 0.024
Negative 1
Smoking
Non-smoker 0 1.235 (0.517–2.954) 0.635 1.613 (0.568–4.581) 0.369 0.465 (0.090–2.404) 0.361
Smoker 1
Age at surgery
<60 0 0.992 (0.601–1.637) 0.975 1.200 (0.642–2.243) 0.568 1.418 (0.472–4.262) 0.534
³60 1
Sex
Male 0 0.782 (0.336–1.819) 0.568 0.682 (0.255–1.825) 0.446 1.900 (0.363–9.938) 0.447
Female 1
Tumour status
T1 1 1.250 (0.958–1.633) 0.101 1.488 (1.053–2.101) 0.024 0.921 (0.490–1.730) 0.798
T2 2
T3 3
T4 4
Nodal status
N0 0 1.956 (1.533–2.496) <0.001 1.756 (1.316–2.343) <0.001 2.310 (1.248–4.276) 0.008
N1 1
N2 2
N3 3
Differentiation
Well 0 1.313 (0.958–1.633) 0.142 1.413 (0.907–2.203) 0.127 1.202 (0.589–2.453) 0.613
Moderately 1
Poorly 2380 C-I Huang et al
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lung, were considered to regulate not only cell proliferation but
also angiogenesis via vascular endothelial growth factor (Rak et al,
1995). Since angiogenesis is essential for tumour growth and
distant metastasis, mutations of the K-ras gene will induce tumour
aggressiveness (Folkman, 1990).
In conclusion, our study showed that alterations of p16 was one
of the significant factor for a poor prognosis in SCCs, and might
play a specific and important role in SCCs of the lung because of
its high prevalence and significant prognostic value.
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